Thermo Fisher and Patheon submit their $7.2 billion deal for EU review
US biotechnology company Thermo Fisher Scientific's proposed buyout of Dutch drugmaker Patheon has been submitted for EU antitrust review. The European Commission has set an Aug. 25 deadline to decide on...To view the full article, register now.
Already a subscriber? Click here to view full article